SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is surging after announcing preliminary Q3 revenue that significantly exceeded prior guidance and analyst consensus, indicating robust demand for its AI infrastructure solutions. The community is highly bullish, anticipating sustained growth as the company plays a crucial role in the ongoing data center buildout.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending following the FDA's issuance of a Complete Response Letter for its Hunter syndrome gene therapy, RGX-121, citing concerns with trial design and the appropriateness of its surrogate endpoint. The community is actively debating the broader implications for gene therapies, RGNX's financial outlook, and potential impacts on its Duchenne and AbbVie-partnered programs.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings is trending following a drastic stock plunge driven by the abrupt departure of its CFO and general counsel, an SEC investigation into cash management, and an accounting review exposing internal control weaknesses and revised future guidance, sparking intense community debate between those foreseeing catastrophe and others viewing it as an extreme overreaction and buying opportunity.

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

MSLE is actively discussed following its recent NASDAQ listing, a reverse split, and a substantial equity raise. While optimists view the financing as a strong vote of confidence in its "revolutionary" muscle regeneration drug for Duchenne patients and foresee potential acquisition, skeptics caution about dilution and characterize early clinical data as premature hype.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin (BNKR) is seeing significant trending activity with its community actively working to "drop a zero" from its price, driven by excitement over its AI-powered utility, new exchange listings, and ecosystem expansion on the Base chain. Community members are enthusiastically accumulating, citing its undervalued market cap and growing revenue, even amid broader crypto market volatility.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies Inc

The community is actively discussing Rocket Companies following its CEO's optimistic remarks about achieving multi-year highs in mortgage loan volume and gain-on-sale performance, leading to expectations of a significant re-rating as its integrated platform benefits from housing market normalization and industry consolidation.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is trending after announcing strong preliminary revenue results and expanding AI-driven healthcare partnerships, which are seen as catalysts for its growth. The community is actively discussing its significant short interest and recent institutional buying, sparking debate on a potential short squeeze.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health (OSCR) is trending sharply higher after the House passed a bill to extend ACA subsidies, fueling investor optimism for significant upside and a potential short squeeze, though community debate persists on the bill's Senate fate and the company's path to profitability ahead of its upcoming earnings.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify (SPOT) is seeing heated debate leading into its Q4 earnings report, as bullish analysts and the rollout of new AI-powered features and price hikes contend with investor concerns over its valuation and a recent music catalog leak.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is experiencing extreme volatility following a patent infringement lawsuit from Novo Nordisk and FDA scrutiny regarding its compounded semaglutide weight-loss pill, which the company has now ceased offering. The community is fiercely debating whether this represents a fundamental threat and further downside, or an overreaction presenting a significant short squeeze opportunity for a company with strong core business segments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zymeworks Inc. (NASDAQ:ZYME) Given Consensus Recommendation of "Buy" by Brokerages

Shares of Zymeworks Inc. (NASDAQ:ZYME - Get Free Report) have been given an average recommendation of "Buy" by the seven research firms that are currently covering the company, Marketbeat reports...

Tejara Capital Ltd Has $1.46 Million Stock Holdings in Zymeworks Inc. $ZYME

Tejara Capital Ltd trimmed its position in Zymeworks Inc. (NYSE:ZYME - Free Report) by 57.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission...

Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Buy" from Analysts

Shares of Zymeworks Inc. (NYSE:ZYME - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eleven brokerages that are presently covering the stock, MarketBeat.com reports...

Zymeworks (NYSE:ZYME) Shares Down 5.5% - Here's Why

Zymeworks (NYSE:ZYME) Shares Down 5.5% - What's Next...

Zymeworks (NYSE:ZYME) CEO Sells $689,712.08 in Stock

Zymeworks Inc. (NYSE:ZYME - Get Free Report) CEO Kenneth Galbraith sold 30,424 shares of the firm's stock in a transaction on Monday, January 12th. The stock was sold at an average price of $22.67...

Zymeworks Inc. (NASDAQ:ZYME) Given Consensus Rating of "Buy" by Analysts

Zymeworks Inc. (NASDAQ:ZYME - Get Free Report) has been given a consensus rating of "Buy" by the seven research firms that are currently covering the firm, MarketBeat Ratings reports. One equities...

Zymeworks (NYSE:ZYME) Insider Paul Andrew Moore Sells 9,560 Shares

Zymeworks Inc. (NYSE:ZYME - Get Free Report) insider Paul Andrew Moore sold 9,560 shares of the business's stock in a transaction dated Monday, January 12th. The stock was sold at an average price of...

Zymeworks (NYSE:ZYME) EVP Jeffrey Smith Sells 9,310 Shares

Zymeworks Inc. (NYSE:ZYME - Get Free Report) EVP Jeffrey Smith sold 9,310 shares of Zymeworks stock in a transaction on Monday, January 12th. The stock was sold at an average price of $22.67, for a...

Insider Selling: Zymeworks (NYSE:ZYME) CEO Sells 30,424 Shares of Stock

Zymeworks Inc. (NYSE:ZYME - Get Free Report) CEO Kenneth Galbraith sold 30,424 shares of Zymeworks stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average...

Zymeworks Inc. (NYSE:ZYME - Get Free Report) has been given a consensus recommendation of "Buy" by the eleven ratings firms that are covering the firm, Marketbeat.com reports. Eleven research...

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Zymeworks BC Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$22.51
Prev Close	$22.72
Open	$22.52
Dividend Yield	0.00%
50-Day Moving Average	$24.93
Beta	0.91
Avg. Volume	970,910.05
PE Ratio	-26.83

52-Week High	$28.49
52-Week Low	$9.03
Market Capitalization	$1.71B
EPS (Annual)	-$1.62
Price to Book	5.37
Revenue Per Employee	$266,797.20
Enterprise Value/EBITDA	N/A

ZYME
Zymeworks Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ZYME News

ZYMEZymeworks Inc